All three are buys, but for different reasons.Fears of a recession did not materialize this year. However, it's always worth it for investors to buy shares of companies that can perform well during economic downturns. Solid dividend stocks that routinely increase their payouts are especially attractive in that regard, since they tend to have businesses equipped to withstand challenging times.Let's discuss three stocks to buy to prepare your portfolio for any recession that may lay ahead: Microsoft (MSFT 0.5 ...

High-rolling investors have positioned themselves bullish on Merck & Co (NYSE:MRK), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MRK often signals that someone has privileged information.Today, Benzinga's options scanner spotted 9 options trades for Merck & Co. This is not a typical pattern.The sentiment among these m ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Youcare Pharmaceutical Group Co., Ltd. 悅康藥業集團股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of China with lim ...

Core Viewpoint - Sanofi is set to acquire Dynavax for approximately $2.2 billion, enhancing its vaccine portfolio amid changing vaccine policies in the US [1][4] Group 1: Acquisition Details - The acquisition price is $15.50 per share in cash, with the deal expected to close in the first quarter of 2026 [1] - Sanofi will gain Dynavax's hepatitis B vaccine HEPLISAV-B, which was approved in the US in 2017 and in Europe in 2021 [2] - Sanofi currently lacks a hepatitis B vaccine in its portfolio, having previously partnered with MSD for a vaccine that is now solely commercialized by MSD [2] Group 2: Product and Market Insights - HEPLISAV-B is administered in a two-dose regimen within one month, contrasting with competitors GSK's Engerix-B and MSD's Recombivax HB, which require three doses over six months [3] - HEPLISAV-B generated sales of $268.4 million in 2024, with Dynavax projecting net product revenue of $305 million to $325 million for 2025 [3] - GlobalData forecasts that HEPLISAV-B will achieve annual sales of $677 million by 2031 [3] Group 3: Industry Context and Regulatory Changes - The acquisition comes amid significant regulatory changes, as the CDC has altered its guidance, no longer recommending hepatitis B vaccination for all US newborns, leading to volatility in the vaccine sector [4] - Analyst Matt Phipps noted that the deal value is slightly below the net present value for HEPLISAV-B, but the acquisition aligns with addressing regulatory concerns and investor expectations for value creation [4] Group 4: Future Prospects - Dynavax's pipeline includes a shingles vaccine candidate, Z-1018, currently in Phase I/II trials, which has shown comparable efficacy to GSK's Shingrix while having fewer adverse reactions [5] - The shingles market is significant, with Shingrix generating £3.4 billion globally for GSK in 2024, indicating the potential market size for Z-1018 [6]

December 26, 2025 01:59 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 12/19) was +1.1% vs. +1.0% last wk and +0.8% over the past 12 wks. GILD's Yeztugo vs. Descovy vs. Apretude launch comparison chart ( Exhibit 4 ). GILD's Yeztugo (lenacapavir) was approved on 6/18/2025. Latest week total TRx (oral + injectable) were ~780 vs. ~800 previous week, and last week TRx for injectable ...

Core Insights - Mind Medicine (MindMed) is advancing its lead candidate MM120, an orally disintegrating tablet for treating generalized anxiety disorder (GAD) and major depressive disorder (MDD) [1] Pipeline Development - Two pivotal phase III studies, Voyage and Panorama, are currently enrolling participants for MM120 ODT in GAD, with the last new drug approval for this condition occurring in 2007 [2] - Phase II study data for MM120 ODT showed efficacy significantly surpassing the current standard of care and a favorable tolerability profile [2] - Top-line data from the Voyage study is expected in the first half of 2026, while Panorama's data is anticipated in the second half of 2026 [3] - The phase III Emerge study for MM120 ODT in MDD has enrolled faster than expected, with top-line data now projected for mid-2026, earlier than previously anticipated [3] - A second phase III study, Ascend, for MDD is planned to start in mid-2026 [3] Financial Performance - MindMed's stock has increased by 101.2% over the past six months, outperforming the industry average increase of 27.6% [4] - The company secured $258.9 million in financing, enhancing its balance sheet and enabling accelerated development of MM120 [5] Additional Pipeline Asset - MindMed's second asset, MM402, is being developed for autism spectrum disorder, with a phase II study expected to begin by the end of 2025 [5] - The year 2026 is projected to be transformational for MindMed with three pivotal data readouts anticipated [5]

Philadelphia, Pennsylvania--(Newsfile Corp. - December 29, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

Key Takeaways Novo Nordisk won FDA approval for oral Wegovy, the first GLP-1 pill cleared for chronic weight management.NVO's oral Wegovy is cheaper to produce, needle-free, no refrigeration, and priced near $149 monthly. Healthcare ETFs like THNR may gain as demand rises in the intensifying obesity drug race. The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s (NVO) oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. Th ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Rezolute to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Far ...

Core Insights - Novo Nordisk has faced significant challenges over the past 18 months, including clinical setbacks, disappointing financial results, and a loss of market share in its key therapeutic area, leading to a notable decline in stock price [1] - Recent regulatory approval for an oral version of Wegovy, the first oral GLP-1 approved for weight management, has positively impacted Novo Nordisk's share price, increasing it by as much as 8% in one day [1][3] Group 1: Product Developments - Novo Nordisk primarily generates revenue from GLP-1 products, including Wegovy, which is used for diabetes treatment and weight management [2] - The newly approved oral Wegovy is expected to attract more patients by eliminating the need for injections, making it easier and cheaper to manufacture at scale [4] - The approval of oral Wegovy provides Novo Nordisk with a first-mover advantage in the oral weight loss market, potentially helping the company regain market share lost to competitors [5] Group 2: Competitive Landscape - Eli Lilly, a major competitor, is also advancing in the weight loss market with its application for orforglipron, a weight loss pill that has shown promising results in clinical trials [7] - The competitive dynamics in the weight management market are intensifying, with both companies vying for a larger share of the growing demand for weight loss therapies [6][7]